Skip to main content

Table 1 Comparisons between patients with response and non-response to NSAIDs after PSM

From: Exploring potential neuroimaging biomarkers for the response to non-steroidal anti-inflammatory drugs in episodic migraine

 

Responders

(n = 59)

Non-responders

(n = 59)

z/χ2

p value

Age (years)

35.00 (16.50)

33.00 (15.50)

-0.059

0.953

Sex (female/male)

49/10

49/10

0.000

1.000

Education (years)

12.00 (7.00)

12.00 (4.00)

-0.073

0.942

Disease duration (years)

8.00 (14.00)

7.00 (12.00)

-0.197

0.844

VAS (scores)

6.00 (2.00)

6.00 (2.50)

-0.120

0.904

Frequency (days/month)

3.00 (2.50)

4.00 (2.00)

-0.027

0.978

Attack time (hours)

15.00 (12.00)

12.00 (16.00)

-1.255

0.209

MIDAS (scores)

20.00 (35.00)

21.00 (35.00)

-0.226

0.821

HIT-6 (scores)

62.00 (15.00)

61.00 (15.00)

-0.299

0.765

GAD-7 (scores)

5.00 (6.00)

6.00 (3.00)

-0.124

0.901

PHQ-9 (scores)

7.00 (8.00)

7.00 (3.50)

-0.443

0.658

PSQI (scores)

7.00 (6.50)

7.00 (4.50)

-0.311

0.756

  1. Continuous variables conforming to the normal distribution are presented as mean (standard deviation); and continuous variables conforming to the non-normal distribution are presented as median (interquartile range)
  2. GAD-7 Generalized Anxiety Disorder 7-Item, HIT-6 Headache Impact Test 6-Item, MIDAS Migraine Disability Assessment Scale, NSAIDs non-steroidal anti-inflammatory drugs, PHQ-9 Patient Health Questionnaire 9-Item, PSM propensity score matching, PSQI Pittsburgh Sleep Quality Index, VAS Visual Analogue Scale